title: Vemurafenib significantly decreases glomerular filtration rate.
authors.affiliation: Department of Dermatology, Paul Sabatier-Toulouse IlI University, Larrey hospital, Toulouse, France.
authors.forename: C
authors.initials: C
authors.lastname: Uthurriague
authors.forename: S
authors.initials: S
authors.lastname: Thellier
authors.forename: D
authors.initials: D
authors.lastname: Ribes
authors.forename: L
authors.initials: L
authors.lastname: Rostaing
authors.forename: C
authors.initials: C
authors.lastname: Paul
authors.forename: N
authors.initials: N
authors.lastname: Meyer
mesh_terms: D000328:Adult; D000368:Aged; D000419:Albuminuria / Q000453:epidemiology / Q000503:physiopathology; D005260:Female; D005919:Glomerular Filtration Rate / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D015994:Incidence; D007211:Indoles / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D007668:Kidney / Q000187:drug effects* / Q000503:physiopathology; D008297:Male; D008545:Melanoma / Q000188:drug therapy / Q000473:pathology; D008875:Middle Aged; D009367:Neoplasm Staging; D047428:Protein Kinase Inhibitors / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D011507:Proteinuria / Q000453:epidemiology / Q000503:physiopathology; D012189:Retrospective Studies; D012878:Skin Neoplasms / Q000188:drug therapy / Q000473:pathology; D013449:Sulfonamides / Q000009:adverse effects / Q000494:pharmacology* / Q000627:therapeutic use; D000077484:Vemurafenib
chemical_list: D007211:Indoles; D047428:Protein Kinase Inhibitors; D013449:Sulfonamides; D000077484:Vemurafenib